Overall summary of first and second vaccine doses administered to the study population as of October 3, 2021.
| Any Vaccine Type | General Population, n = 12,435,914 | RA, n = 138,304 | AS, n = 28,509 | PsA, n = 17,646 | PsO, n = 182,319 | IBD, n = 108,792 |
|---|---|---|---|---|---|---|
| Received at least 1 dose | 10,208,667 (82.1) | 122,893 (88.9) | 24,911 (87.4) | 15,995 (90.6) | 159,220 (87.3) | 94,613 (87.0) |
| Vaccine product of 1st dosea | ||||||
| BNT162b2 | 7,384,130 (72.3) | 89,816 (73.1) | 17,650 (70.9) | 11,361 (71.0) | 113,523 (71.3) | 67,535 (71.4) |
| mRNA-1273 | 1,958,127 (19.2) | 23,225 (18.9) | 4,564 (18.3) | 2,746 (17.2) | 28,655 (18.0) | 17,604 (18.6) |
| ChAdOx1 nCoV-19 | 862,543 (8.4) | 9,831 (8.0) | 2,689 (10.8) | 1,886 (11.8) | 17,011 (10.7) | 9,456 (10.0) |
| Received 2 doses | 9,694,968 (78.0) | 119,198 (86.2) | 24,082 (84.5) | 15,556 (88.2) | 153,521 (84.2) | 91,187 (83.8) |
| Interval between 2 doses, days | 60 (44–76) | 70 (54–83) | 64 (50–78) | 67 (54–79) | 65 (50–79) | 64 (49–78) |
| Individuals ≥ 40 days overdue for 2nd doseb | 237,665 (2.4) | 2,280 (1.9) | 412 (1.7) | 256 (1.6) | 2,827 (1.8) | 1,724 (1.9) |
Values are expressed as n (%) or median (IQR).
↵aIn total, the vaccine type was another product or unknown vaccine product in 3867 individuals.
↵bPotential vaccine dropouts who failed to complete the 2-dose series. AS: ankylosing spondylitis; IBD: inflammatory bowel disease; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.